Proposals & Awards
Megan K. Crowley Award for Patient Advocacy
Congrats to Megan K. Crowley! Megan received the Megan K. Crowley Award for Patient Advocacy, whose recipient Megan Crowley, ND ’19 is a tireless patient advocate and President of the Notre Dame Chapter of Make a Wish Foundation that aims to grant a wish of every child diagnosed with a life threatening condition. CRND is honored Megan came to study at Notre Dame.
John M. and Mary Jo Boler Rare Disease Research Award
Congrats to Gabrielle O'Dougherty! Gabrielle received the John M. and Mary Jo Boler Rare Disease Research Award in honor of the parents of Matt Boler and Jill McCormack and the resonance of their generous philanthropy with rare diseases. The recipient Gabrielle O’Dougherty ND ’19 in partnership with a local patient family and their neurosurgeon developed a unique case report on Shprintzen Goldberg Syndrome (SGS) that is currently under revision for publication. O’Dougherty et al, Case Report: Complications of Insufficient Dura and Blood Loss during Surgical Intervention in Shprintzen-Goldberg Syndrome.
Dr. Xin Lu, the John M. and Mary Jo Boler Assistant Professor of Biological Sciences, in the Boler-Parseghian Center for Rare and Neglected Diseases, has been awarded a Young Investigator Award from the Indiana Clinical and Translational Sciences Institute (CTSI).
"His work investigates ways to develop cures for rare cancers that are very poorly understood and extremely difficult to treat," said Kasturi Haldar, Rev. Julius A. Nieuwland C.S.C. professor of biological sciences and James Parsons and Carrie Quinn director of the Boler-Parseghian Center for Rare and Neglected Diseases. "He is a leading expert in developing mouse models that can mimic rare cancers caused by human mutations, in which to test new therapies."Dr. Xin Lu, the John M. and Mary Jo Boler Assistant Professor of Biological Sciences, in the Boler-Parseghian Center for Rare and Neglected Diseases, has been awarded a Young Investigator Award from the Indiana Clinical and Translational Sciences Institute (CTSI).
Lu seeks to understand and target the tumor microenvironment. Many drugs that can kill cancers are toxic, but if they can selectively be delivered to the cancerous cell and released inside of it, then the drug will more precisely kill the tumor. This reduces the chance that the drug will harm healthy tissue. Lu has proposed a strategy of coupling drugs to antibodies that can recognize targets on prostate cancer cells.
RareND Team builds ZEBRA, award-winning app in Notre Dame App Challenge and goal for Precision Medicine!
The ND App Challenge was sponsored by the Office of the Executive Vice President, and organized by SAP, Innovation Park at Notre Dame and the Office of Information Technologies. In the challenge, over 70 teams from across Notre Dame created mobile apps responsive to President Rev. John I. Jenkins, C.S.C. call to action “I now ask all of you to join me in supporting these collaborative efforts to advance our vision of Notre Dame as a powerful force to heal, unify and enlighten our world.”Congratulations to Anna Volk, Will Langbo, Kim Trouch, and Katherine Inskeep for an important advocacy tool for patient-centered medicine and winning 3rd place in the first ND App Challenge!Precision Medicine is a revolution in health care. It seeks the zebra because it looks for what makes you unique. This is the rare disease model. In a rare disease, every patient unique. This is why the individual patient is at the center of rare disease treatment, empowered to collaborate to fund research and share their complex biological and health data in a network of doctors, patients and advocates, in search of transformative outcomes. "When you hear hoof beats, think of horses not zebras" was how Dr. Theodore Woodward at the University of Maryland counseled medical interns in 1940s. But the best of medicine today seeks the zebra in all of us. This is the goal of ‘Precision Medicine’, where we leave behind the ‘average’ patient and instead focus on individual differences in genes and other molecular determinants, as well as the impact of environment and life style, to understand a patient’s disease and how to treat it.